/PRNewswire/ Arthrosi Therapeutics, Inc. welcomes Robert Thomas Keenan, MD, MPH, MBA, as Chief Medical Officer. Dr. Keenan has spent nearly 20 years in the.
/PRNewswire/ Arthrosi Therapeutics, Inc. today announced a joint venture in Guangzhou, China with Guangzhou Ruiao Biopharmaceutical Technology Co., Ltd. ("a.
/PRNewswire/ Arthrosi Therapeutics, Inc. announced results from its Phase 2a study investigating the efficacy and safety of its potent urate lowering agent.
Arthrosi s New Molecule AR882 for Gout Shows Blockbuster-Potential streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Arthrosi Expands Disease Expertise with New Board of Director Appointment
News provided by
Share this article
Share this article
SAN DIEGO, April 20, 2021 /PRNewswire/ Arthrosi Therapeutics, Inc. today announced the appointment of James Mackay, PhD, to its board of directors. Dr. Mackay brings more than 30 years of in-depth experience to the team, as they reach Phase2b in the clinical development of AR882, the next generation molecule for the treatment of gout. We are pleased to welcome Dr. Mackay to the Arthrosi board, said Co-Founder and CEO Litain Yeh. James brings a significant amount of experience, playing an instrumental role in the development and commercialization of the last two gout treatments. His experience, vision, and knowledge of the gout market will help guide our future success.